Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The point for patients is this: progression on one endocrine therapy doesn't close the door on hormone-driven treatment
4 Treatment groups Experimental Treatment Active Control Placebo Group Participants will receive cagrilintide and semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks in the main phase
This will require granular strategic patient segmentation informed by multiple data sources with RWD playing a key role, e.g., anonymised, longitudinal patient-level Rx data, claims data or EMR, combined with primary market research
The RXIV Infusions team works closely with clients to provide guidance on dosing schedules, dietary adjustments, and supportive strategies that make semaglutide easier to tolerate
Bonus Tip: L-Carnitine Coffee Yes, its a thingand its trending
Asano et al
